연구성과로 돌아가기

2024 연구자 정보 (50 / 1079)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Moon, Yong Wha
(Moon, YW) ⓘ 		CHA Bundang Med Ctr, Internal Med Dept, Hematol & Oncol, Seongnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Nam, Myungwoo
(Nam, M) ⓘ 		ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria
[JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) ⓘ 		SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Noh, Sung Hoon
(Noh, SH) ⓘ 		Yonsei Univ Hlth Syst, Gangnam Severance Hosp, Dept Surg, Seoul, South Korea ⓘ
ⓘ 		0000-0003-4386-6886
Noh, Sung Hoon ⓘ 		[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
O'Brien, Susanne
(O'Brien, S) ⓘ 		Vaccitech, Harwell, Oxon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ tom.evans@barinthusbio.com; ⓘ
Park, Chohyun
(Park, C) ⓘ 		Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Surg, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Park, Ho Yong
(Park, HY) ⓘ 		Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea
Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Breast & Thyroid Surg, Daegu, South Korea
Kyungpook Natl Univ, Chilgok Hosp, Hoguk Ro 807, Daegu 41404, South Korea ⓘ 		AAP-2225-2021
P-5981-2015
PARK, HO-YONG
PARK, JUN-YOUNG ⓘ
ⓘ 		[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer
[JCR상위 36.0] Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for targeting suspicious axillary lymph nodes in patients with breast cancer
[JCR상위 18.7] A Comparison Study of Nipple-Areolar Complex Measurement: Light Detection and Ranging (LiDAR) Camera Versus Photometry
[JCR상위 8.2] Robot-Assisted Latissimus Dorsi Flap Harvest for Partial Breast Reconstruction: Comparison With Endoscopic and Conventional Approaches
[JCR상위 70.5] Postoperative Scar Management Using Laser Therapy for Breast Reconstruction With Latissimus Dorsi Flap
[JCR상위 44.0] Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer
[JCR상위 65.0] Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer
[JCR상위 49.8] Usefulness of cordless ultrasonic cutting energy devices in endoscopic nipple-sparing mastectomy: a retrospective study
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
SURGERY
MEDICINE, RESEARCH & EXPERIMENTAL
CELL BIOLOGY ⓘ 		phy123@knu.ac.kr;
daniel302@naver.com;rjyflying@naver.com;lambyang@knu.ac.kr;leejspo@knu.ac.kr;
lambyang@knu.ac.kr;
yschae@knu.ac.kr;
jjh01@knu.ac.kr;
j.lee@knu.ac.kr; ⓘ
Park, Hyung Seok
(Park, HS) ⓘ 		Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Surg, Seoul, South Korea ⓘ C-6000-2008
Park, Hong-Gyu ⓘ 		0000-0001-5322-6036
Park, Hyung Seok ⓘ 		[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06)
[JCR상위 0.2] Minimal Access vs Conventional Nipple-Sparing Mastectomy ⓘ 		SCIE ⓘ 0.2 ONCOLOGY
SURGERY ⓘ 		imgenius@yuhs.ac;j.lee@knu.ac.kr; ⓘ
Park, Jee-Young Nora
(Park, JYN) ⓘ 		ⓘ AAA-1951-2022
Park, Jung Hwan ⓘ
ⓘ 		[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer
[JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. ⓘ 		SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Park, Ji-young
(Park, JY) ⓘ 		ⓘ P-5981-2015
PARK, JUN-YOUNG ⓘ
ⓘ 		[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Park, Junhyun
(Park, J) ⓘ 		ⓘ KSM-8932-2024
Park, Jun Won ⓘ
ⓘ 		[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ⓘ
Park, Keon Uk
(Park, KU) ⓘ 		Keimyung Univ, Dongsan Hosp, Daegu, South Korea
Keimyung Univ, Coll Med, Dept Internal Med, Div Hematol Oncol,Dongsan Hosp, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
[JCR상위 5.6] Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		jasonksa@korea.ac.kr;khpark@korea.ac.kr; ⓘ
Park, Kyong Hwa
(Park, KH) ⓘ 		Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea
Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol, Seoul, South Korea ⓘ
ⓘ 		0000-0002-2464-7920
PARK, KYONG HWA ⓘ 		[JCR상위 1.7] A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
[JCR상위 5.6] Age- and ethnic-driven molecular and clinical disparity of East Asian breast cancers ⓘ 		SCIE ⓘ 1.7 ONCOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		jasonksa@korea.ac.kr;khpark@korea.ac.kr; ⓘ
Park, Neung Hwa
(Park, NH) ⓘ 		Ulsan Univ Hosp, Ulsan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ limys@amc.seoul.kr; ⓘ
Park, Young-Kyu
(Park, YK) ⓘ 		Chonnam Natl Univ, Dept Surg, Med Sch, Hwasun, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY ⓘ SCIE ⓘ 1.7 ONCOLOGY ⓘ ykkang@amc.seoul.kr; ⓘ
Peng, Cheng-Yuan
(Peng, CY) ⓘ 		China Med Univ Hosp, Taichung, Taiwan ⓘ LDR-1674-2024
Peng, Chengyuan ⓘ
ⓘ 		[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis ⓘ SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ limys@amc.seoul.kr; ⓘ
페이지 이동: